法国ANSM调查:68Ga-PSMA-11 PET/CT在生化复发前列腺癌中的显像方案、检出率与安全性
基于法国6中心1084例近期18F-氟胆碱PET/CT阴性或可疑的生化复发前列腺癌患者,68Ga-PSMA-11 PET/CT总体阳性率为68%,中位血清PSA为1.7 ng/mL时31%呈寡转移模式;阳性率与血清PSA、年龄、初始治疗、FCH结果及既往复发相关,不同显像方案间无显著差异,未报告不良事件。
要点
- FCH阴性或可疑的生化复发患者中,PSMA-11 PET/CT总体阳性率达68%。
- 阳性率随血清PSA升高而增加(<0.2 ng/mL为41%,≥2 ng/mL为81%)。
- 不同显像方案(注射活度、对比剂/呋塞米、采集时间点)阳性率无显著差异。
核心结论
- 基于FCH PET/CT筛选后,PSMA-11 PET/CT在血清PSA<1 ng/mL时阳性率与独立报道无差异,在≥1 ng/mL时略低。
- 根据生化临床背景,约四分之一至三分之一的病例观察到寡转移模式,为靶向治疗提供依据。
- 系统性地采用双/三时间点采集或使用对比剂和/或呋塞米未显著提高PSMA-11 PET/CT阳性率,应个体化决定。
研究设计与样本
- 法国6个中心在前3年使用期间前瞻性向法国药品管理局(ANSM)提交患者数据以授权, pooled分析1084例PSMA-11 PET/CT。
- 纳入近期FCH PET/CT结果为阴性或可疑的生化复发前列腺癌患者。
主要发现
- 总体阳性率为68%,中位血清PSA为1.7 ng/mL时,31%的病例呈寡转移模式(1-3个病灶)。
- 阳性率与血清PSA显著相关:<0.2 ng/mL为41%,≥2 ng/mL为81%。
- 阳性率与患者年龄、初始治疗(前列腺切除术后64% vs 未行前列腺切除术85%)、FCH结果(阴性62% vs 可疑82%)及既往生化复发(首次63% vs 既往72%)相关。
- 注射活度、对比剂和/或呋塞米使用、剂量长度乘积、单次或多时间点图像采集等显像方案间阳性率无显著差异。
- PSMA-11注射后未报告不良事件,即使联合对比剂和/或呋塞米。
关键数值与推荐
- 总体阳性率68%(1084例)。
- 血清PSA<0.2 ng/mL时阳性率41%,≥2 ng/mL时81%。
- 前列腺切除术后阳性率64%,未行前列腺切除术85%。
- FCH阴性者阳性率62%,FCH可疑者82%。
- 首次生化复发阳性率63%,既往生化复发72%。
临床怎么用
- 对于FCH PET/CT阴性或可疑的生化复发前列腺癌患者,可考虑行68Ga-PSMA-11 PET/CT以定位病灶。
- 血清PSA水平可帮助预测PSMA-11 PET/CT阳性率,PSA≥2 ng/mL时阳性率较高。
- 不推荐常规系统性地增加采集时间点或使用对比剂/呋塞米,应根据个体情况决定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11. PATIENTS AND METHODS: Six centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patient's data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed. RESULTS: (1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1-3 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if ≥ 2 ng/mL), to patients' age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide. CONCLUSION: Compared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA ≥ 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases.
引用
- Chevalme YM, Boudali L, Gauthé M, et al. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. Eur J Nucl Med Mol Imaging. 2021. PMID: 33416958. doi:10.1007/s00259-020-05086-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。